To compare the in vitro activity of moxalactam (LY127935), a new broadspectrum antimicrobial agent, with cefazolin, amikacin, tobramycin, carbenicillin, piperacillin, and ticarcillin, each drug was tested against 420 bacterial isolates from the blood of septic patients. Standard broth dilution methods were used to determine minimum inhibitory and bactericidal concentrations. LY127935 was as active as the aminoglycosides against aerobic gram-negative organisms, including Pseudomonas aeruginosa, and was at least 10-fold more active than the other fl-lactam agents against these bacteria. LY127935 was the most active agent tested against Bacteroides fragilis; its activity against all otter anaerobic bacteria and Staphylococcus aureus was similar to those of the other agents tested. All streptococci, however, grew at higher concentrations of LY127935 than any other drug, and Streptococcus faecalis and Listeria monocytogenes were not inhibited at the highest concentration tested (minimum inhibitory concentration, >64 ,ig/ ml). Although a greater proportion of blood culture isolates were susceptible to LY127935 than to any other drug tested, LY127935 does not have a sufficiently broad spectrum of in vitro activity to be recommended safely alone for empirical treatment of sepsis of unknown etiology.
Several new antimicrobial agents have been developed in recent years to provide a nontoxic alternative to available agents for treating resistant Enterobacteriaceae, Pseudomonas aeruginosa, and anaerobic organisms. Cefamandole and cefoxitin have broader activity in vitro than older cephalosporins, but they are still secondary choices to more established and cheaper drugs (1) . Piperacillin (4, 11, 18 ) and furazlocillin (4, 18) are active in vitro against many aerobic gram-negative rods and anaerobic organisms, but resistant strains occur. SCE-129, a new cephalosporin, is very active against P. aeruginosa, but it is not active against other gram-negative rods (8 Similar concentrations of LY127935, carbenicillin, and ticarcillin inhibited S. aureus, whereas cefazolin was 10-fold more active. Streptococci grew at higher concentrations of LY127935 than any of the other agents studied except the aminoglycosides. Listeria monocytogenes, enterococci, and Corynebacterium spp. grew at the highest concentration of LY127935 tested (64 ig/Iml).
Miniimal bactericidal concentrations were generally close to MICs with MBC-to-MIC ratios of less than 2 (Tables 1 and 2 
DISCUSSION
Our results support the impression that LY127935 has excellent broad-spectrum in vitro activity. LY127935 inhibited and killed a greater proportion of all isolates than any other agent we tested. This greater activity is especially important in that we tested only organisms that caused documented clinical sepsis in proportion to their actual frequency of isolation at our hospitals. This proportion is quite comparable to that which has been previously reported in both teaching (17) and community hospitals elsewhere (5, 10) and in patients with bacteremia complicating neoplastic disease (12) . In a similar study testing the same 420 bacterial isolates at our hospital against cefamandole, cefoxitin, gentamicin, and ampicillin, cefamandole demonstrated the widest spectrum of in vitro activity (S. Mirrett and L. B. Reller, unpublished data). However, LY127935 still inhibited a greater number of isolates tested. LY127935 demonstrated excellent in vitro activity against all aerobic gram-negative organisms, including P. aeruginosa. The MICs of LY127935 and the aminoglycosides were similar for all the organisms. As shown by others, the activity ofpiperacillin against P. aeruginosa was also similar to those of LY127935 and the aminoglycosides (6, 11, 18 ). However, LY127935 was 10-fold or more active than piperacillin against other aerobic gram-negative rods.
LY127935 performed well against all anaerobic organisms, especially the Bacteroides fragilis group, with the lowest MICs of the agents tested. Previous studies have shown carbenicillin and ticarcillin to be suitable agents for treating anaerobic infections (9, (14) (15) (16) . Given the greater in vitro activity of LY127935, especially against Bacteroides spp., it may provide a useful clinical alternative.
Against gram-positive organisms, however, LY127935 showed less activity. Importantly, all enterococci, L. monocytogenes, and Corynebacterium spp. were resistant in vitro.
In summary, LY127935 offers a broad spectrum of antimicrobial coverage in vitro. However, 13% of all bacteria tested were not inhibited by LY127935.
